Astragalus polysaccharides exert protective effects in newborn rats with bronchopulmonary dysplasia by upregulating the expression of EGFL7 in lung tissue

Wang,Xiao-Hong; Huang,Wei-Min

doi:10.3892/ijmm.2014.1951

Astragalus polysaccharides exert protective effects in newborn rats with bronchopulmonary dysplasia by upregulating the expression of EGFL7 in lung tissue

Authors:
- Xiao-Hong Wang
- Wei-Min Huang
View Affiliations

Affiliations: Department of Neonatology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong 510515, P.R. China
Published online on: September 30, 2014 https://doi.org/10.3892/ijmm.2014.1951
Pages: 1529-1536

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of this study was to explore the effects of Astragalus polysaccharides (APS) on the mRNA expression of epidermal growth factor-like domain 7 (EGFL7) in lung tissue in newborn rats with bronchopulmonary dysplasia (BPD). For this purpose, a total of 96 newborn SD rats were randomly divided into 4 groups (n=24): the control group, air room plus APS group, BPD group and the APS group (20 mg/kg/day). Lung tissues were obtained on days 4, 10 and 14 after birth. Morphological changes were observed and the protein and mRNA expression levels of EGFL7, Bax and Bcl-2 were determined. The rats in the BPD group (BPD induced by hyperoxia) presented with an arrest in alveolar and vascular development and low mRNA and protein expression levels of of EGFL7, Bcl-2 and high levels of Bax compared with the rats in the control group. However, lung damage in the APS intervention group was attenuated compared with the BPD group. The protein and mRNA expression levels of EGFL7 and Bcl-2 were also increased and the level of Bax was decreased in the APS intervention group (P<0.01) compared with the BPD model group after birth on days 4, 10 and 14. Our data demonstrate that APS reduce airway remodeling and alveolar damage by upregulating the expression of EGFL7 and exert protective effects against BPD in neonatal rats. Thus, APS may have potential for use as a therapeutic strategy for BPD.

View Figures

View References

1	Northway WH Jr, Rosan RC and Porter DY: Pulmonary disease following respirator therapy of hyaline-membrane disease. Bronchopulmonary dysplasia. N Engl J Med. 276:357–368. 1967. View Article : Google Scholar : PubMed/NCBI
2	Jobe AH: The new bronchopulmonary dysplasia. Curr Opin Pediatr. 23:167–172. 2011. View Article : Google Scholar
3	Gien J and Kinsella JP: Pathogenesis and treatment of bronchopulmonary dysplasia. Curr Opin Pediatr. 23:305–313. 2011. View Article : Google Scholar : PubMed/NCBI
4	Hayes D Jr, Feola DJ, Murphy BS, Shook LA and Ballard HO: Pathogenesis of bronchopulmonary dysplasia. Respiration. 79:425–436. 2010. View Article : Google Scholar
5	Tang JR, Markham NE, Lin YJ, et al: Inhaled nitric oxide attenuates pulmonary hypertension and improves lung growth in infant rats after neonatal treatment with a VEGF receptor inhibitor. Am J Physiol Lung Cell Mol Physiol. 287:L344–L351. 2004. View Article : Google Scholar : PubMed/NCBI
6	Foidart JM, Schaaps JP, Chantraine F, et al: Dysregulation of anti-angiogenic agents (sFlt-1, PLGF, and sEndoglin) in preeclampsia: a step forward but not the definitive answer. J Reprod Immunol. 82:106–111. 2009. View Article : Google Scholar : PubMed/NCBI
7	Speer CP: Chorioamnionitis, postnatal factors and proinflammatory response in the pathogenetic sequence of bronchopulmonary dysplasia. Neonatology. 95:353–361. 2009. View Article : Google Scholar : PubMed/NCBI
8	Soll RF: Corticosteroids for the treatment and prevention of bronchopulmonary dysplasia. Neonatology. 98:109–110. 2010. View Article : Google Scholar : PubMed/NCBI
9	Jensen EA and Schmidt B: Epidemiology of bronchopulmonary dysplasia. Birth Defects Res A Clin Mol Teratol. 100:145–157. 2014. View Article : Google Scholar
10	Xu D, Perez RE, Ekekezie II, Navarro A and Truog WE: Epidermal growth factor-like domain 7 protects endothelial cells from hyperoxia-induced cell death. Am J Physiol Lung Cell Mol Physiol. 294:L17–L23. 2008. View Article : Google Scholar : PubMed/NCBI
11	Asikainen TM and White CW: Pulmonary antioxidant defenses in the preterm newborn with respiratory distress and bronchopulmonary dysplasia in evolution: implications for antioxidant therapy. Antioxid Redox Signal. 6:155–167. 2004. View Article : Google Scholar : PubMed/NCBI
12	Welty SE: Antioxidants and oxidations in bronchopulmonary dysplasia: there are no easy answers. J Pediatr. 143:697–698. 2003. View Article : Google Scholar : PubMed/NCBI
13	Welty SE and Smith CV: Rationale for antioxidant therapy in premature infants to prevent bronchopulmonary dysplasia. Nutr Rev. 59:10–17. 2001. View Article : Google Scholar : PubMed/NCBI
14	Chu Chu, Qi Lian-Wen, Liu E-Hu, Li Bin, Gao Wen and Li Ping: Radix Astragali (Astragalus): latest advancements and trends in chemistry, analysis, pharmacology and pharmacokinetics. Curr Org Chem. 14:1792–1807. 2010. View Article : Google Scholar
15	Yang ZG, Sun HX and Fang WH: Haemolytic activities and adjuvant effect of Astragalus membranaceus saponins (AMS) on the immune responses to ovalbumin in mice. Vaccine. 23:5196–5203. 2005.PubMed/NCBI
16	Xu XL, Ji H, Gu SY, Shao Q, Huang QJ and Cheng YP: Cardioprotective effects of Astragali Radix against isoproterenol-induced myocardial injury in rats and its possible mechanism. Phytother Res. 22:389–394. 2008.
17	Ohkawara S, Okuma Y, Uehara T, Yamagishi T and Nomura Y: Astrapterocarpan isolated from Astragalus membranaceus inhibits proliferation of vascular smooth muscle cells. Eur J Pharmacol. 525:41–47. 2005.
18	Yan F, Zhang QY, Jiao L, Han T, Zhang H, Qin LP and Khalid R: Synergistic hepatoprotective effect of Schisandrae lignans with Astragalus polysaccharides on chronic liver injury in rats. Phytomedicine. 16:805–813. 2009.
19	Wang S, Li J, Huang H, Gao W, Zhuang C, Li B, Zhou P and Kong D: Anti-hepatitis B virus activities of astragaloside IV isolated from radix Astragali. Biol Pharm Bull. 32:132–135. 2009. View Article : Google Scholar : PubMed/NCBI
20	Mao XQ, Yu F, Wang N, Wu Y, Zou F, Wu K, Liu M and Ouyang JP: Hypoglycemic effect of polysaccharide enriched extract of Astragalus membranaceus in diet induced insulin resistant C57BL/6J mice and its potential mechanism. Phytomedicine. 16:416–425. 2009.PubMed/NCBI
21	Auyeung KK, Cho CH and Ko JK: A novel anticancer effect of Astragalus saponins: transcriptional activation of NSAID-activated gene. Int J Cancer. 125:1082–1091. 2009. View Article : Google Scholar : PubMed/NCBI
22	Yu DH, Bao YM, Wei CL and An LJ: Studies of chemical constituents and their antioxidant activities from Astragalus mongholicus Bunge. Biomed Environ Sci. 18:297–301. 2005.PubMed/NCBI
23	Choi SI, Heo TR, Min BH, Cui JH, Choi BH and Park SR: Alleviation of osteoarthritis by calycosin-7-O-beta-D-glucopyranoside (CG) isolated from Astragali radix (AR) in rabbit osteoarthritis (OA) model. Osteoarthritis Cartilage. 15:1086–1092. 2007. View Article : Google Scholar : PubMed/NCBI
24	Song JZ, Yiu HH, Qiao CF, Han QB and Xu HX: Chemical comparison and classification of Radix Astragali by determination of isoflavonoids and astragalosides. J Pharm Biomed Anal. 47:399–406. 2008. View Article : Google Scholar : PubMed/NCBI
25	Xu DJ, Xia Q, Wang JJ and Wang PP: Molecular weight and monosaccharide composition of Astragalus polysaccharides. Molecules. 13:2408–2415. 2008. View Article : Google Scholar : PubMed/NCBI
26	Huang WM, Liang YQ and Wang XH: Antioxidant and anti-inflammatory effects of Astragalus polysaccharide on EA.hy926 cells. Exp Ther Med. 36:199–203. 201
27	Yang B, Xiao B and Sun T: Antitumor and immunomodulatory activity of Astragalus membranaceus polysaccharides in H22 tumor-bearing mice. Int J Biol Macromol. 62:287–290. 2013.
28	Robbesom AA, Versteeg EM, Veerkamp JH, et al: Morphological quantification of emphysema in small human lung specimens: comparison of methods and relation with clinical data. Mod Pathol. 16:1–7. 2003. View Article : Google Scholar : PubMed/NCBI
29	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
30	Morcillo EJ, Estrela J and Cortijo J: Oxidative stress and pulmonary inflammation: pharmacological intervention with antioxidants. Pharmacol Res. 40:393–404. 1999. View Article : Google Scholar : PubMed/NCBI
31	D’Angio CT and Maniscalco WM: The role of vascular growth factors in hyperoxia-induced injury to the developing lung. Front Biosci. 7:D1609–D1623. 2002.PubMed/NCBI
32	Coalson JJ, Winter VT, Siler-Khodr T and Yoder BA: Neonatal chronic lung disease in extremely immature baboons. Am J Respir Crit Care Med. 160:1333–1346. 1999. View Article : Google Scholar : PubMed/NCBI
33	Krasteva I, Nikolova I, Danchev N and Nikolov S: Phytochemical analysis of ethyl acetate extract from Astragalus corniculatus Bieb. and brain antihypoxic activity. Acta Pharm. 54:151–156. 2004.
34	Bhatt AJ, Pryhuber GS, Huyck H, Watkins RH, Metlay LA and Maniscalco WM: Disrupted pulmonary vasculature and decreased vascular endothelial growth factor, Flt-1, and TIE-2 in human infants dying with bronchopulmonary dysplasia. Am J Respir Crit Care Med. 164:1971–1980. 2001. View Article : Google Scholar : PubMed/NCBI
35	Soncin F, Mattot V, Lionneton F, Spruyt N, Lepretre F, Begue A and Stehelin D: VE-statin, an endothelial repressor of smooth muscle cell migration. EMBO J. 22:5700–5711. 2003. View Article : Google Scholar : PubMed/NCBI
36	Campagnolo L, Leahy A, Chitnis S, Koschnick S, Fitch MJ, Fallon JT, Loskutoff D, Taubman MB and Stuhlmann H: EGFL7 is a chemoattractant for endothelial cells and is up-regulated in angiogenesis and arterial injury. Am J Pathol. 167:275–284. 2005. View Article : Google Scholar : PubMed/NCBI
37	De Maziere A, Parker L, Van Dijk S, Ye W and Klumperman J: Egfl7 knockdown causes defects in the extension and junctional arrangements of endothelial cells during zebrafish vasculogenesis. Dev Dyn. 237:580–591. 2008.PubMed/NCBI
38	Parker LH, Schmidt M, Jin SW, et al: The endothelial-cell-derived secreted factor Egfl7 regulates vascular tube formation. Nature. 428:754–758. 2004. View Article : Google Scholar : PubMed/NCBI
39	Hockenbery DM, Oltvai ZN, Yin XM, Milliman CL and Korsmeyer SJ: Bcl-2 functions in an antioxidant pathway to prevent apoptosis. Cell. 75:241–251. 1993. View Article : Google Scholar : PubMed/NCBI
40	Oltval ZN, Milliman CL and Korsmeyer SJ: Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programed cell death. Cell. 74:609–619. 1993. View Article : Google Scholar : PubMed/NCBI
41	Kroon AA and Post M: Apoptotic cell death in bronchopulmonary dysplasia. Curr Pediatr Rev. 7:285–292. 2011. View Article : Google Scholar
42	Schmidt M, Paes K, De Maziere A, et al: EGFL7 regulates the collective migration of endothelial cells by restricting their spatial distribution. Development. 134:2913–2923. 2007. View Article : Google Scholar : PubMed/NCBI